Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation (CTOT-21)

NCT02711826 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT02711826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02711826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation (CTOT-21)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1/2
Overall status
Completed
Start date
September 20, 2016
Completion date
August 4, 2023
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adult living donor kidney transplant recipients, kidney transplant, living kidney donor, renal transplant